

Change of number of shares and votes in Xbrane

The number of shares and votes in Xbrane has changed following the issue of 515,108 shares on September 27, 2023 through a directed Set-Off Issue to the Company's lender CVI Investments, Inc. The Company chose to settle the installment of SEK 12,812,487 for the Convertible Bonds with shares. The subscription price in the Set-Off Issue amounts to SEK 24.8734 per share, which equals 90% of the market price (lowest VWAP during the six trading-day period immediately preceding the applicable date).

As of 30 September 2023, the total number of shares and votes in the Company amounts to 29,731,112. The Company's registered share capital amounts to approximately SEK 6,665,301.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-30 14:43 CEST.

Attachments

[Change of number of shares and votes in Xbrane](#)